Bevacizumab Biosimilars Market Size to Reach USD 5.94 Billion by 2035 | SNS Insider

The U.S. bevacizumab biosimilars market is forecast to rise from $0.87B in 2025 to $2.41B by 2035, while Europe is expected to grow from $0.63B to $1.61B. Growth is attributed to increasing biosimilar adoption, higher oncology treatment demand, and favorable reimbursement policies. Overall, the outlook is constructive but based on forecast rather than a specific corporate catalyst.

Analysis

This is more a pricing/distribution story than a true demand inflection. The economic upside accrues to the lowest-cost manufacturers and the reimbursement stack, while the originator cash flow gets carved up by continued share migration and weaker price realization; the headline growth number likely overstates net profit pool expansion because biosimilar revenue growth often comes with brutal ASP compression.

The clean loser is Roche/Genentech’s residual bevacizumab economics, but the broader second-order effect is that oncology buyers become more comfortable swapping into biosimilars across the entire anti-VEGF and mAb aisle. That can pressure future contracting for adjacent biologics and force originators to defend share with deeper rebates, which hurts margin even where unit volumes hold. Large distributors and infusion providers may see higher throughput, but the spread is thin and the real benefit is operational, not earnings-transformative.

Over the next 1-3 months, this is unlikely to move a broad biotech tape unless accompanied by CMS or payer rule changes. The structural read-through is 6-18 months: Europe’s tender-heavy market should remain margin-hostile, and the U.S. only becomes meaningfully more attractive if reimbursement keeps favoring biosimilar uptake without a corresponding originator rebate response. The thesis is falsified if originator pricing stabilizes via aggressive contracting or if payer formulary decisions slow conversion; conversely, faster-than-expected ASP erosion would confirm that revenue growth is masking weaker dollar economics.

Key Decisions for Investors

• Pair trade: long AMGN / short RHHBY over 6-12 months. Use it as a relative-value expression of biosimilar commercialization versus originator erosion; risk/reward is better than a naked short because Amgen’s broader pipeline can offset some sector noise.
• If already short Roche ADRs, keep the position but add on rallies only after guidance or U.S. sales data confirm continued bevacizumab share loss. The trade works best if the market starts to price the decline as a slow burn rather than a one-quarter event.
• Do not force a broad biotech long on this print alone; XBI/IBB are poor vehicles because the move is too narrow and the profit pool is too small. Wait for concrete evidence that biosimilar adoption is lifting earnings at a named manufacturer before taking beta.
• Watch CMS reimbursement and major payer formulary updates as the key catalyst. If reimbursement stays favorable while originator rebates fail to stop conversion, the next leg is another round of oncology biologic margin compression; if not, this becomes a non-event.